Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...